toggle

Sangamo BioSciences Inc

Latest Sangamo BioSciences Inc News and Updates

Company & Industry Overviews
The Evolution of Hemophilia Treatment—And What It Means for BioMarin
BioMarin’s BMN 270 is a gene therapy being investigated for hemophilia A. On April 20, it announced early data of the phase-1 and phase-2 study of BMN 270.
By Jillian DabneyJuly 7 2016, Updated 12:05 p.m. ET
Company & Industry Overviews
Could Gene Therapy Be a Next-Generation Treatment for Hemophilia?
Gene therapy is the emerging platform for hemophilia care. If approved, it would be a paradigm.
By Jillian DabneyApril 28 2016, Updated 11:07 a.m. ET

ABOUT Market Realist
About Us
Privacy Policy
Terms of Use
DMCA

CONNECT with Market Realist

© Copyright 2025 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.

Sangamo BioSciences Inc

The Evolution of Hemophilia Treatment—And What It Means for BioMarin

Could Gene Therapy Be a Next-Generation Treatment for Hemophilia?